Health
Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC – OncLive
Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation…
Because no standard approaches exist for patients with EGFR-mutated nonsmall cell lung cancer (NSCLC) who progress on standard frontline osimertinib (Tagrisso), repeat genomic testing should be done to identify potential resistance mechanisms that can help guide the next step in the treatment journey, Rami Manochakian, MD.
This is a very hot topic now. There are some potential rare, resistant mechanisms that could be a secondary actionable mutation such as MET amplification where you can potentially…
-
Noosa News23 hours agoAbusive bus driver fired by council loses appeal
-
General20 hours agoIran’s currency at record low as tensions run high
-
General24 hours agoTwo groups of men evicted from Rabbitohs and Roosters NRL clash after wild brawl
-
General19 hours agoLabor to pledge $2.3 billion to subsidise home batteries